J. Kyle Wathen

2.9k total citations · 1 hit paper
32 papers, 2.0k citations indexed

About

J. Kyle Wathen is a scholar working on Statistics and Probability, Pulmonary and Respiratory Medicine and Management Science and Operations Research. According to data from OpenAlex, J. Kyle Wathen has authored 32 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Statistics and Probability, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Management Science and Operations Research. Recurrent topics in J. Kyle Wathen's work include Statistical Methods in Clinical Trials (17 papers), Sarcoma Diagnosis and Treatment (8 papers) and Advanced Causal Inference Techniques (7 papers). J. Kyle Wathen is often cited by papers focused on Statistical Methods in Clinical Trials (17 papers), Sarcoma Diagnosis and Treatment (8 papers) and Advanced Causal Inference Techniques (7 papers). J. Kyle Wathen collaborates with scholars based in United States, Canada and United Kingdom. J. Kyle Wathen's co-authors include Peter F. Thall, Laurence H. Baker, Robert S. Benjamin, Dennis A. Priebat, Robert G. Maki, Shreyaskumar Patel, Brian L. Samuels, Denise K. Reinke, Scott M. Schuetze and Martee L. Hensley and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

J. Kyle Wathen

32 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002

2007 531 citations Robert G. Maki, J. Kyle Wathen et al. Journal of Clinical Oncology profile →

Peers

J. Kyle Wathen

PRM

ONCOL

PFM

CCM

Mark D. Rothmann United States

Patricia Guyot France

Denise K. Reinke United States

Ker‐Ai Lee Canada

Lilla Di Scala Switzerland

Jee Soo Kim South Korea

Akihiro Hirakawa Japan

H. Samuel Wieand United States

Alex Smith United States

Lindsay A. Renfro United States

Mark D. Rothmann United States

J. Kyle Wathen

324 ×0.3

PRM

443 ×0.7

ONCOL

382 ×0.6

154 ×0.5

PFM

54 ×0.2

CCM

Citations per year, relative to J. Kyle Wathen J. Kyle Wathen (= 1×) peers Mark D. Rothmann

Countries citing papers authored by J. Kyle Wathen

Since Specialization

Citations

This map shows the geographic impact of J. Kyle Wathen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Kyle Wathen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Kyle Wathen more than expected).

Fields of papers citing papers by J. Kyle Wathen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Kyle Wathen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Kyle Wathen. The network helps show where J. Kyle Wathen may publish in the future.

Co-authorship network of co-authors of J. Kyle Wathen

This figure shows the co-authorship network connecting the top 25 collaborators of J. Kyle Wathen. A scholar is included among the top collaborators of J. Kyle Wathen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Kyle Wathen. J. Kyle Wathen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wathen, J. Kyle, et al.. (2023). A platform trial approach to proof-of-concept (POC) studies in autism spectrum disorder: Autism spectrum POC initiative (ASPI). Contemporary Clinical Trials Communications. 32. 101061–101061. 1 indexed citations

Park, Jay, Edward J. Mills, & J. Kyle Wathen. (2023). Introduction to Adaptive Trial Designs and Master Protocols. Cambridge University Press eBooks. 5 indexed citations

Park, Jay, Behnam Sharif, Ofir Harari, et al.. (2022). Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional Trials. JAMA Network Open. 5(7). e2221140–e2221140. 25 indexed citations

Wathen, J. Kyle & Peter F. Thall. (2017). A simulation study of outcome adaptive randomization in multi-arm clinical trials. Clinical Trials. 14(5). 432–440. 52 indexed citations

Fox, Patricia S., et al.. (2015). Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Annals of Oncology. 26(8). 1621–1628. 79 indexed citations

Schuetze, Scott M., J. Kyle Wathen, David R. Lucas, et al.. (2015). SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma. Cancer. 122(6). 868–874. 79 indexed citations

Morgan, Caroline, Susan Huyck, Martin Jenkins, et al.. (2014). Adaptive Design: Results of 2012 Survey on Perception and Use. Therapeutic Innovation & Regulatory Science. 48(4). 473–481. 46 indexed citations

Hensley, Martee L., J. Kyle Wathen, Robert G. Maki, et al.. (2013). Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma. Cancer. 119(8). 1555–1561. 116 indexed citations

Freireich, Emil J., et al.. (2012). A prospective, randomized, double-blind study, comparing unirradiated to irradiated white blood cell transfusions in acute leukemia patients. Leukemia. 27(4). 861–865. 8 indexed citations

10.

Chugh, Rashmi, J. Kyle Wathen, Shreyaskumar Patel, et al.. (2010). Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial. Clinical Cancer Research. 16(19). 4884–4891. 166 indexed citations

11.

Thall, Peter F. & J. Kyle Wathen. (2008). Bayesian designs to account for patient heterogeneity in phase II clinical trials. Current Opinion in Oncology. 20(4). 407–411. 7 indexed citations

12.

Wathen, J. Kyle & Peter F. Thall. (2008). Bayesian adaptive model selection for optimizing group sequential clinical trials. Statistics in Medicine. 27(27). 5586–5604. 17 indexed citations

13.

Maki, Robert G., J. Kyle Wathen, Shreyaskumar Patel, et al.. (2007). Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. Journal of Clinical Oncology. 25(19). 2755–2763. 531 indexed citations breakdown →

14.

Nakayama, Kazutaka, Nizar M. Tannir, Ping Liu, et al.. (2007). Natural History of Metastatic Renal Cell Carcinoma in Patients Who Underwent Consultation for Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 13(8). 975–985. 4 indexed citations

15.

Wathen, J. Kyle, Peter F. Thall, John D. Cook, & Elihu H. Estey. (2007). Accounting for patient heterogeneity in phase II clinical trials. Statistics in Medicine. 27(15). 2802–2815. 29 indexed citations

16.

Chugh, Rashmi, Robert G. Maki, Denise K. Reinke, et al.. (2006). A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. Journal of Clinical Oncology. 24(18_suppl). 9515–9515. 15 indexed citations

17.

Cheung, Ying Kuen, Lurdes Y. T. Inoue, J. Kyle Wathen, & Peter F. Thall. (2005). Continuous Bayesian adaptive randomization based on event times with covariates. Statistics in Medicine. 25(1). 55–70. 43 indexed citations

18.

Thall, Peter F. & J. Kyle Wathen. (2005). Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments. Statistics in Medicine. 24(13). 1947–1964. 43 indexed citations

19.

Li, Zhiyong, Nuhad K. Ibrahim, J. Kyle Wathen, et al.. (2004). Colitis in patients with breast carcinoma treated with taxane‐based chemotherapy. Cancer. 101(7). 1508–1513. 24 indexed citations

20.

Thall, Peter F., J. Kyle Wathen, B. Nebiyou Bekele, et al.. (2003). Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Statistics in Medicine. 22(5). 763–780. 139 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact